Puma Biotechnology | PBYI - Current Assets


Puma Biotechnology reported $143.58M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Incyte USD 5.48B 460.36M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Moderna USD 5.77B 774M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Takeda JPY 3.09T 25.94B Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026